Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings Inc (RANI) is a clinical-stage biotherapeutics leader developing oral alternatives to injectable biologic medications through its patented RaniPill technology. This page provides investors and industry observers with timely updates on corporate milestones, clinical trial progress, and strategic initiatives shaping the future of non-invasive drug administration.
Access official press releases, financial disclosures, and third-party analysis covering RANI's advancements in transforming treatments for chronic diseases. Key updates include trial results for oral biologic formulations, intellectual property developments, partnership announcements with pharmaceutical collaborators, and quarterly performance reports.
Bookmark this page for streamlined tracking of RANI's progress in addressing critical challenges in drug delivery. Return regularly to monitor how the company's capsule-based technology could impact treatment adherence, patient comfort, and the broader $500B+ biologics market.
Rani Therapeutics (NASDAQ: RANI) has announced a Research Agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies. The agreement, signed on August 13, 2024, covers two molecules with undisclosed targets. Initial analysis shows the RaniPill® delivery system achieved comparable bioavailability to subcutaneous delivery for both studied molecules.
Rani has previously evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill® capsule. The collaboration aims to leverage Rani's expertise in developing oral antibodies, peptides, and large proteins with high bioavailability alongside Chugai's technology-driven drug discovery approach.
Rani Therapeutics (NASDAQ: RANI) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its oral biologics delivery platform. The company demonstrated successful preclinical results for RT-114, a GLP-1/GLP-2 dual agonist showing bioequivalence to subcutaneous administration, and successful oral delivery of semaglutide via the RaniPill® capsule.
Financial highlights include:
- Cash position of $27.6 million as of December 31, 2024
- Contract revenue of $1.0 million for Q4 and full year 2024
- R&D expenses decreased to $26.7 million in 2024 from $39.6 million in 2023
- Net loss of $56.6 million for 2024, improved from $67.9 million in 2023
The company completed two equity offerings in 2024 raising approximately $20.0 million in gross proceeds. Rani expects its current cash position to fund operations into Q3 2025 and plans to initiate a Phase 1 study of RT-114 for obesity treatment in mid-2025.
Rani Therapeutics (RANI) announced promising preclinical data for RT-114, their oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule. The study demonstrated bioequivalence with subcutaneously administered PG-102, achieving 111% relative bioavailability and comparable pharmacokinetic profiles.
Key findings from the canine study include:
- 90% delivery success rate (9 out of 10 canines)
- Identical average peak weight loss of 6.7% in both oral and subcutaneous groups
- Well-tolerated with no safety concerns
Previous Phase 1 trials of subcutaneous PG-102 showed weight loss in obese patients, averaging 4.8% and reaching up to 8.7% after five weeks. The company plans to initiate a Phase 1 clinical trial for RT-114 in mid-2025, targeting obesity treatment with a convenient oral dosing regimen.
Rani Therapeutics (Nasdaq: RANI), a clinical-stage biotherapeutics company specializing in oral delivery of biologics and drugs, has scheduled the release of its fourth quarter and full year 2024 financial results on Monday, March 31, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Interested parties can access the webcast through the 'Investors' section of Rani's website at www.ranitherapeutics.com. A replay will be available in the investor relations section following the call.
Rani Therapeutics (RANI) announced successful preclinical data for oral delivery of semaglutide using their RaniPill® HC platform. The study demonstrated that oral semaglutide (RT-116) achieved comparable bioavailability (107%) and pharmacokinetics to subcutaneous administration.
The crossover study involved eight canines receiving 0.5mg doses, with successful delivery in 7 of 8 subjects. Both oral and subcutaneous administration groups showed similar weight loss patterns and decreases in serum triglycerides and cholesterol. The RaniPill® HC was well-tolerated with no serious adverse events.
The company aims to develop a once-weekly oral administration of semaglutide, potentially offering a more convenient alternative to current injectable treatments. Rani also announced plans to initiate a Phase 1 study for RT-114, their GLP-1/GLP-2 dual agonist for obesity treatment, in 2025.
Rani Therapeutics (NASDAQ: RANI) reported Q3 2024 financial results and corporate updates. The company completed two equity offerings raising $20.0 million in gross proceeds, extending cash runway into Q3 2025. Cash position was $30.4 million as of September 30, 2024. Q3 net loss decreased to $12.7 million from $18.3 million year-over-year. R&D expenses decreased to $6.2 million from $11.2 million, while G&A expenses reduced to $5.6 million from $6.6 million. The company announced new preclinical data supporting transenteric delivery of GLP-1 incretin triagonist and plans to initiate Phase 1 trial of RT-114 for obesity treatment in 2025.
Rani Therapeutics Holdings (Nasdaq: RANI), a clinical-stage biotherapeutics company, will participate in three upcoming investor conferences.
The company's management team will attend the UBS Global Healthcare Conference at Terranea Resort, Rancho Palos Verdes, CA on November 14, 2024, at 10:15am PT, the Stifel Healthcare Conference at Lotte New York Palace Hotel, New York, NY on November 18, 2024, at 4:10pm ET, and the 7th Annual Evercore ISI HealthCONx Conference at The Loews Coral Gables Hotel, Coral Gables, FL on December 4, 2024, at 12:55pm ET.
Each event will feature a fireside chat and 1x1 meetings. Interested parties can register and access live webcasts via the “Events” section of the Rani Therapeutics website. Webcast replays will be available post-event.
Rani Therapeutics Holdings (Nasdaq: RANI) has announced a $10.0 million registered direct offering of its Class A common stock and warrants. The company will sell 3,000,000 shares of common stock and pre-funded warrants for 333,333 shares, along with Series C common warrants for up to 3,333,333 shares. Each share or pre-funded warrant is priced at $3.00, bundled with a Series C warrant. The Series C warrants have a $3.00 exercise price and a 5-year expiration. Rani will also cancel all outstanding Series A warrants issued on July 22, 2024. Maxim Group is the sole placement agent, with the offering expected to close around October 16, 2024. The proceeds will be used to support Rani's clinical-stage biotherapeutics work on oral delivery of biologics and drugs.
Rani Therapeutics, a Nasdaq-listed clinical-stage biotherapeutics company (RANI), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company, which focuses on oral delivery of biologics and drugs, will be represented by CEO Talat Imran and CFO Svai Sanford in a fireside chat.
The event is scheduled for Thursday, October 17, 2024, from 11:30 am to 12:00 pm E.T. in Track 2. Interested parties can access the live webcast of the conference through a provided registration link. This participation highlights Rani Therapeutics' engagement with the investment community and its commitment to sharing insights about its innovative approach to drug delivery.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
